The labels give 2022 as its first U.S. approval.1,2
How the molecule is built
The labels describe tirzepatide as based on the sequence of GIP, the glucose-dependent insulinotropic polypeptide. It carries a 20-carbon fatty acid attached through a linker, which makes it bind to albumin in the blood and prolongs its half-life, and it contains the amino acid Aib in positions 2 and 13. Its molecular weight is 4,813.53 daltons, a little larger than semaglutide at 4,113.58.1,3
About 99% of tirzepatide in the blood is bound to albumin. The half-life is about 5 days, the level peaks 8 to 72 hours after an injection, and with weekly doses it reaches a steady state after 4 weeks. After an injection under the skin, 80% of the dose reaches the blood.1
How it works
Tirzepatide binds to and activates both the GIP and the GLP-1 receptor, the targets of the body's own hormones. On blood sugar, it raises insulin release in the first and second phases after a meal and lowers glucagon, both only when glucose is high. It also slows the emptying of the stomach, an effect the label says is largest after the first dose and smaller over time.1
On weight, the Zepbound label says tirzepatide decreases calorie intake, likely by acting on appetite, and that both receptors are found in brain areas involved in appetite regulation. It notes that GLP-1 is a regulator of appetite and that nonclinical studies suggest GIP may add to the regulation of food intake. As with semaglutide, the label says weight is lost with greater loss of fat mass than of lean mass.2
The two brands
| Brand | Approved for | Doses | Youngest age |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | 2.5 to 15 mg a week | 10 |
| Zepbound | Weight, obstructive sleep apnea | 2.5 to 15 mg a week | Adults only |
Current FDA labels. Children aged 10 and older with type 2 diabetes go up to 10 mg of Mounjaro.1,2
Both brands start at 2.5 mg a week and rise in steps of 2.5 mg every 4 weeks or more. Each label says not to combine it with another tirzepatide product or with a GLP-1 receptor agonist.1,2 Our page on Mounjaro and Zepbound explains where the two labels part.
Against semaglutide
Two trials assigned people to tirzepatide or semaglutide directly. In SURPASS-2, 1,879 adults with type 2 diabetes on metformin took tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks. HbA1c fell by 2.0 to 2.3 points on tirzepatide against 1.9 on semaglutide, and weight by 7.6 to 11.2 kg against 5.7 kg.1,4
In SURMOUNT-5, 751 adults with obesity and without diabetes took the highest dose they tolerated of tirzepatide, 10 or 15 mg, or of semaglutide, 1.7 or 2.4 mg, for 72 weeks. Weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. The trial was open-label and funded by the maker of tirzepatide.5 Our page on Ozempic and Zepbound sets the two trials side by side, and switching from Wegovy to Zepbound covers the move between them. In the earlier SURMOUNT-1, against placebo, weight fell by 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg over the same 72 weeks, and by 3.1% on placebo.6
Safety in brief
Both tirzepatide labels carry the boxed warning about thyroid C-cell tumors seen in rodents and rule the drug out for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The most common side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain.1 Because it slows stomach emptying, the labels ask people on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase.1,2
Compounded tirzepatide
Compounded tirzepatide is not an FDA-approved product. FDA declared the tirzepatide shortage over in December 2024, and by May 31, 2026 it had received more than 730 adverse event reports about compounded tirzepatide.7,8 Our page on compounded GLP-1 medicines covers what FDA still allows.
Sources
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 8.3, 11, 12 and 14. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 8 and 12. accessdata.fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 11. accessdata.fda.gov
- Fr铆as JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. nejm.org
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
Related analyses
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Wegovy vs Mounjaro: two drugs, two labels, and the trials that compared them
Switching from Wegovy to Zepbound: the starting dose, the timing, and what the evidence covers
Log each tirzepatide dose and see your estimated level day by day.
Open Dose Insider